ASMB—Guess remains to be seen if 48-week data will look any better for the lead on HBsAg declines but, given all these follow-on drugs, I'm just going to continue to remain skeptical.
It may be that core inhibitors are indeed a propitious way to address HBV (especially when combined with a nuke), but that ASMB’s CpAM compounds are suboptimal compared to those from another company :- )
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.